Top-line results from TauRx Therapeutics Ltd.’s second Phase 3 study in Alzheimer’s disease presented at CTAD

Top-line results from TauRx Therapeutics Ltd.’s second Phase 3 study in Alzheimer’s disease presented at CTAD

ABERDEEN, Scotland and Singapore, 17th December 2016 – Top-line results from TauRx Therapeutics Ltd.’s second Phase 3 study in Alzheimer’s disease, study TRx-237-005, were presented on 8th December at the 9th Clinical Trials on Alzheimer’s Disease (CTAD) 2016 meeting in San Diego,CA, USA1. The study investigated the efficacy and safety of LMTX® in 800 patients with mild Alzheimer’s disease at a dose of either 100 mg or 4 mg (intended as the control dose) twice daily over an 18-month treatment period.

Read more here.

Top-line results second Phase 3 study CTAD

Top-line results from TauRx Therapeutics Ltd.’s second Phase 3 study in Alzheimer’s disease, study TRx-237-005, were presented on 8th December at the 9th Clinical Trials on Alzheimer’s Disease (CTAD)